Phosphodiesterase type 5 and cancers: progress and challenges

Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano

doi:10.18632/oncotarget.21837

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Phosphodiesterase type 5 and cancers: progress and challenges

Ines Barone _, Cinzia Giordano, Daniela Bonofiglio, Sebastiano Andò and Stefania Catalano

PDF | HTML | How to cite

Oncotarget. 2017; 8:99179-99202. https://doi.org/10.18632/oncotarget.21837

Metrics: PDF 1711 views | HTML 6542 views | ?

Abstract

Ines Barone1, Cinzia Giordano2, Daniela Bonofiglio1, Sebastiano Andò1 and Stefania Catalano1

1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy

2Centro Sanitario, University of Calabria, Arcavacata di Rende, CS, Italy

Correspondence to:

Ines Barone, email: [email protected]

Stefania Catalano, email: [email protected]

Keywords: phosphodiesterase, cancer, targeted therapy, biomarkers, chemoprevention

Received: June 20, 2017 Accepted: September 23, 2017 Published: October 12, 2017

ABSTRACT

Cancers are an extraordinarily heterogeneous collection of diseases with distinct genetic profiles and biological features that directly influence response patterns to various treatment strategies as well as clinical outcomes. Nevertheless, our growing understanding of cancer cell biology and tumor progression is gradually leading towards rational, tailored medical treatments designed to destroy cancer cells by exploiting the unique cellular pathways that distinguish them from normal healthy counterparts. Recently, inhibition of the activity of phosphodiesterase type 5 (PDE5) is emerging as a promising approach to restore normal intracellular cyclic guanosine monophosphate (cGMP) signalling, and thereby resulting into the activation of various downstream molecules to inhibit proliferation, motility and invasion of certain cancer cells. In this review, we present an overview of the experimental and clinical evidences highlighting the role of PDE5 in the pathogenesis and prevention of various malignancies. Current data are still not sufficient to draw conclusive statements for cancer patient management, but could provide further rational for testing PDE5-targeting drugs as anticancer agents in clinical settings.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21837

Publication Alerts

Reviews:

Phosphodiesterase type 5 and cancers: progress and challenges

Abstract